DE19921567A1
(de)
*
|
1999-05-11 |
2000-11-16 |
Basf Ag |
Verwendung von Phthalazine-Derivaten
|
EP1263458B1
(en)
|
2000-03-08 |
2005-11-16 |
Novo Nordisk A/S |
Lowering serum cholesterol
|
WO2003031432A1
(en)
|
2001-10-12 |
2003-04-17 |
Novo Nordisk A/S |
Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
|
WO2003055482A1
(en)
|
2001-12-21 |
2003-07-10 |
Novo Nordisk A/S |
Amide derivatives as gk activators
|
ATE491703T1
(de)
*
|
2002-04-30 |
2011-01-15 |
Kudos Pharm Ltd |
Phthalazinonderivate
|
CA2744893A1
(en)
|
2002-06-27 |
2004-01-08 |
Novo Nordisk A/S |
Aryl carbonyl derivatives as glucokinase activators
|
MXPA06003474A
(es)
|
2003-09-30 |
2006-06-05 |
Novo Nordisk As |
Agonistas de receptores de melanocortina.
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
MXPA06007667A
(es)
|
2004-01-06 |
2006-09-01 |
Novo Nordisk As |
Heteroaril-ureas y su uso como activadores de glucocinasa.
|
WO2005105785A2
(en)
|
2004-05-04 |
2005-11-10 |
Novo Nordisk A/S |
Indole derivatives for treatment of obesity
|
EP1758575A1
(en)
|
2004-06-11 |
2007-03-07 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
US8263551B2
(en)
|
2004-11-22 |
2012-09-11 |
Novo Nordisk A/S |
Soluble, stable insulin-containing formulations with a protamine salt
|
JP2008521864A
(ja)
|
2004-12-03 |
2008-06-26 |
トランステック・ファーマ、インコーポレイテッド |
ヘテロ芳香族グルコキナーゼ活性化剤
|
RU2499795C2
(ru)
|
2005-07-04 |
2013-11-27 |
Хай Пойнт Фармасьютикалс, ЛЛС |
Антагонисты гистаминовых н3-рецепторов
|
EP1904467B1
(en)
|
2005-07-14 |
2013-05-01 |
Novo Nordisk A/S |
Urea glucokinase activators
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
AU2006342449B2
(en)
|
2005-11-17 |
2012-03-01 |
Eli Lilly And Company |
Glucagon receptor antagonists, preparation and therapeutic uses
|
KR101280333B1
(ko)
|
2006-03-28 |
2013-07-02 |
하이 포인트 파마슈티칼스, 엘엘씨 |
히스타민 h3 수용체 활성을 갖는 벤조티아졸
|
WO2007137968A1
(en)
|
2006-05-29 |
2007-12-06 |
High Point Pharmaceuticals, Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
CA2669884A1
(en)
|
2006-11-15 |
2008-05-22 |
High Point Pharmaceuticals, Llc |
Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
|
US8022066B2
(en)
|
2006-11-15 |
2011-09-20 |
High Point Pharmaceuticals, Llc |
2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
|
US8318778B2
(en)
|
2007-01-11 |
2012-11-27 |
Novo Nordisk A/S |
Urea glucokinase activators
|
WO2011104378A1
(en)
|
2010-02-26 |
2011-09-01 |
Novo Nordisk A/S |
Peptides for treatment of obesity
|
BR112012021231A2
(pt)
|
2010-02-26 |
2015-09-08 |
Basf Plant Science Co Gmbh |
método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
|
CA2792663A1
(en)
|
2010-03-26 |
2011-09-29 |
Novo Nordisk A/S |
Novel glucagon analogues
|
WO2012104834A1
(en)
|
2011-02-03 |
2012-08-09 |
Pharmedica Ltd. |
New oral dissolving films for insulin administration, for treating diabetes
|
CN103596583B
(zh)
|
2011-03-28 |
2016-07-27 |
诺沃—诺迪斯克有限公司 |
新型胰高血糖素类似物
|
IN2014CN02448A
(ja)
|
2011-09-23 |
2015-06-19 |
Novo Nordisk As |
|
MX362275B
(es)
|
2013-04-18 |
2019-01-10 |
Novo Nordisk As |
Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
|
CN106536547A
(zh)
|
2014-06-04 |
2017-03-22 |
诺和诺德股份有限公司 |
用于医疗用途的glp‑1/胰高血糖素受体共激动剂
|
EP3596107A1
(en)
|
2017-03-15 |
2020-01-22 |
Novo Nordisk A/S |
Bicyclic compounds capable of binding to melanocortin 4 receptor
|
US20210221867A1
(en)
|
2018-05-15 |
2021-07-22 |
Novo Nordisk A/S |
Compounds Capable of Binding to Melanocortin 4 Receptor
|
WO2020053414A1
(en)
|
2018-09-14 |
2020-03-19 |
Novo Nordisk A/S |
Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
|